Search
for
Sort by
Research 30 of 360
- Pegylated-interferon-α<sub>2a</sub>in clinical practice: how to manage patients suffering from side effects
- Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
- Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C
- Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege
- Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review
- Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report
- Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report
- Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy
- Clinical Characteristics and Factors Associated with Hair Loss Severity in Chronic Hepatitis B Patients Receiving Pegylated Interferon-Alpha: A Retrospective Cohort Study
- Dermatological Manifestations of Pegylated Interferon alfa2a and Ribavirin Combination Therapy in Chronic HCV Patients
- Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon α 2a therapy for chronic hepatitis C virus infection
- Hyperammonemia with Valproic Acid: Colonic Ischemia Associated with “Triptan” Use Visual Side Effects with Pegylated Interferon: Alopecia Areata with Infliximab: Adverse Effects Seen with Medications Used for Irritable Bowel Syndrome
- Cutaneous necrosis after injection of polyethylene glycol–modified interferon alfa
- Alopecia universalis following interferon alfa-2b and ribavirin treatment for hepatitis C.
- Psoriasis and Hepatitis C: Improvement with Interferon
- 만성 B형 간염 환자에서 Pegylated 인터페론 알파2a 치료 중 발생한 원형 탈모
- Follow‐up of Adverse Drug Reactions from Peginterferon alfa‐2b—Ribavirin Therapy
- Widespread Dystrophic-Anagen Alopecia and Drug Eruption due to Usage of PEG-IFN ?-2a /Ribavirin Combination Therapy
- Widespread and eruptive comedonal lesions with alopecia
- Reversible alopecia universalis secondary to PEG-interferon ??-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection
- Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection
- Reversible Alopecia Universalis During Treatment with PEG-Interferon and Ribavirin for Chronic Hepatitis C
- Bullous Lesions at Polyethylene Glycol Interferon-alpha-2a Inoculation Site in a Hepatitis C Virus-infected Subject
- Interferon in the treatment of cutaneous T-cell lymphoma
- Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area
- Zinc: A complementary factor in the treatment of chronic hepatitis C? (Review)
- Trends in Nanotechnology for Practical Applications
- A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer
- A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin
- The influence of interferon on healthy and diseased skin